Diagnosis and Treatment of Prostate Cancer

A special issue of Journal of Clinical Medicine (ISSN 2077-0383).

Deadline for manuscript submissions: closed (20 August 2018)

Special Issue Editor

Nanomedicine and Drug Delivery, School of Pharmacy, Queen’s University Belfast, Belfast, UK
Interests: prostate cancer; nanomedicine; chemotherapy; gene therapy; active targeting; prostate cancer marker; cancer imaging

Special Issue Information

Dear Colleagues,

Prostate Cancer (PC) is the most common type of cancer, and the second leading cause of death in men worldwide. PC has been primarily treated with hormonal therapy and radiotherapy. Hormonal drugs have been developed to block the activity of endogenous testosterone which plays an important role in PC prognosis. This approach is effective at the early stages of the treatment. However, over time, castrate-resistant PC (CRPC) cells emerge, where chemotherapeutics, such as docetaxel, are used as a gold standard to treat advanced and metastatic prostate cancer. Therefore, there is an unmet need to identify new therapeutic targets in PC, and to develop novel drugs and treatment approaches to delay and/or overcome the development of CRPC, which results in cancer metastasis.

Prostate-specific antigen (PSA) is the routine diagnostic test for PC in men, which lacks selectivity. Thus, expensive and invasive techniques, such as MRI imaging and tissue biopsy are still required to confirm the PSA results. More effort is required to look for new reliable markers, and non-invasive diagnostic approaches, that could enhance the selectivity and the sensitivity of PC detection in men. The present Special issue aims to present the latest pre-clinical and clinical research findings in the field of prostate cancer treatment, and diagnosis to enhance the treatment response, reduce side effects, prolong patients’ survival, and improve their quality of life.

Dr. Wafa Al-Jamal
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Advanced prostate cancer
  • Prostate cancer metastasis
  • Androgen-deprivation therapy (ADT)
  • Castrate-resistant prostate cancer (CRPC)
  • Drug resistance
  • Prostate cancer diagnosis
  • PC urine markers
  • PC blood markers
  • PC tissue markers
  • Non-invasive imaging

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop